Alcon (ALC) Investments And Advances : $319 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Alcon Investments And Advances?

Alcon's Investments And Advances for the quarter that ended in Dec. 2023 was $319 Mil.

Alcon's quarterly Investments And Advances stayed the same from Jun. 2023 ($0 Mil) to Sep. 2023 ($0 Mil) but then increased from Sep. 2023 ($0 Mil) to Dec. 2023 ($319 Mil).

Alcon's annual Investments And Advances increased from Dec. 2021 ($52 Mil) to Dec. 2022 ($108 Mil) and increased from Dec. 2022 ($108 Mil) to Dec. 2023 ($319 Mil).

Alcon Investments And Advances Historical Data

The historical data trend for Alcon's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alcon Investments And Advances Chart

Alcon Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

59.00

40.00

52.00

108.00

319.00

Alcon Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Investments And Advances	Get a 7-Day Free Trial															108.00	-	-	-	319.00

Alcon Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Alcon (ALC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Alcon Inc (NYSE:ALC) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

ALC:Mexico ALCz:UK 0A0D:UK ALC:Switzerland

Address

Chemin de Blandonnet 8, Royce Bedward, Vernier, Geneva, CHE, 1214

Website

https://www.alcon.com

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.